REFERENCES

Question 1:

1. Socinski MA, Obasaju C, Gandara D, et al. Clinicopathologic features of advanced squamous NSCLC. *J Thorac Oncol*. 2016;11(9):1411-1422. doi:10.1016/j.jtho.2016.05.024
2. Kashima J, Kitadai R, Okuma Y. Molecular and morphological profiling of lung cancer: A foundation for "next-generation" pathologists and oncologists. *Cancers*. 2019;11(5):599. doi:10.3390/cancers11050599
3. Petersen I. The morphological and molecular diagnosis of lung cancer. *Dtsch Arzteb Int*. 2011;108(31-32):525-531. doi:10.3238/arztebl.2011.0525
4. Suarez E, Knollmann-Ritschel BEC. Squamous cell carcinoma of the lung. *Acad Pathol*. 2017;4. doi:10.1177/2374289517705950
5. Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. *Lung Cancer Amst Neth*. 2013;82(2):179-189. doi:10.1016/j.lungcan.2013.07.025

Question 2:

1. Socinski MA, Obasaju C, Gandara D, et al. Clinicopathologic features of advanced squamous NSCLC. *J Thorac Oncol*. 2016;11(9):1411-1422. doi:10.1016/j.jtho.2016.05.024
2. Sabbula B, Anjum F. Squamous cell lung cancer. *StatPearls Internet*. Published online January 2021. Accessed March 25, 2021. https://pubmed.ncbi.nlm.nih.gov/33232091/
3. Ettinger DS, Wood DE, Aisner DL, Akerley W. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 5.2021. Published June 15, 2021. Accessed March 25, 2021. doi:10.6004/jnccn.2021.0013

Question 3:

1. Kashima J, Kitadai R, Okuma Y. Molecular and morphological profiling of lung cancer: A foundation for "next-generation" pathologists and oncologists. *Cancers*. 2019;11(5):599. doi:10.3390/cancers11050599
2. Ettinger DS, Wood DE, Aisner DL, Akerley W. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 5.2021. Published June 15, 2021. Accessed March 25, 2021. doi:10.6004/jnccn.2021.001
3. Socinski MA, Obasaju C, Gandara D, et al. Clinicopathologic features of advanced squamous NSCLC. *J Thorac Oncol*. 2016;11(9):1411-1422. doi:10.1016/j.jtho.2016.05.024

Question 4:

1. Socinski MA, Obasaju C, Gandara D, et al. Clinicopathologic features of advanced squamous NSCLC. *J Thorac Oncol*. 2016;11(9):1411-1422. doi:10.1016/j.jtho.2016.05.024
2. Ettinger DS, Wood DE, Aisner DL, Akerley W. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 5.2021. Published June 15, 2021. Accessed March 25, 2021. doi:10.6004/jnccn.2021.001

Question 5:

1. Socinski MA, Obasaju C, Gandara D, et al. Clinicopathologic features of advanced squamous NSCLC. *J Thorac Oncol*. 2016;11(9):1411-1422. doi:10.1016/j.jtho.2016.05.024
2. Ettinger DS, Wood DE, Aisner DL, Akerley W. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 5.2021. Published June 15, 2021. Accessed March 25, 2021. doi:10.6004/jnccn.2021.001
3. Hirsh V. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. *Onco Targets Ther*. 2017;10:2513-2526. Published 2017 May 11. doi:10.2147/OTT.S104177

Question 6:

1. Ettinger DS, Wood DE, Aisner DL, Akerley W. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 5.2021. Published June 15, 2021. Accessed March 25, 2021. doi:10.6004/jnccn.2021.001

Question 7:

1. Ettinger DS, Wood DE, Aisner DL, Akerley W. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 5.2021. Published June 15, 2021. Accessed March 25, 2021. doi:10.6004/jnccn.2021.001

Question 8:

1. FDA Press Release. FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%). Published April 11, 2019. Accessed August 11, 2021. https://www.fda.gov/drugs/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1
2. Merck. KEYTRUDA® (pembrolizumab) injection, for intravenous use [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s102lbl.pdf. Revised 08/2021. Accessed August 11, 2021.
3. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet*. 2019;393(10183):1819-1830. doi:10.1016/S0140-6736(18)32409-7
4. Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 testing for lung cancer in 2019: Perspective from the IASLC Pathology Committee. *J Thorac Oncol*. 2020;15(4):499-519. doi:10.1016/j.jtho.2019.12.107

Question 9:

1. Socinski MA, Obasaju C, Gandara D, et al. Clinicopathologic features of advanced squamous NSCLC. *J Thorac Oncol*. 2016;11(9):1411-1422. doi:10.1016/j.jtho.2016.05.024

Question 10:

1. Merck. KEYTRUDA® (pembrolizumab) injection, for intravenous use [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s102lbl.pdf. Revised 08/2021. Accessed August 11, 2021.
2. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet*. 2019;393(10183):1819-1830. doi:10.1016/S0140-6736(18)32409-7
3. Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 testing for lung cancer in 2019: Perspective from the IASLC Pathology Committee. *J Thorac Oncol*. 2020;15(4):499-519. doi:10.1016/j.jtho.2019.12.107
4. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med*. 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865
5. Paz-Ares L, Vicente D, Tafreshi A, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407. *J Thorac Oncol*. 2020;15(10):1657-1669. doi:10.1016/j.jtho.2020.06.015

Question 11:

1. Merck. KEYTRUDA® (pembrolizumab) injection, for intravenous use [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s102lbl.pdf. Revised 08/2021. Accessed August 11, 2021.
2. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med*. 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865
3. Paz-Ares L, Vicente D, Tafreshi A, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407. *J Thorac Oncol*. 2020;15(10):1657-1669. doi:10.1016/j.jtho.2020.06.015

Question 12:

1. Ettinger DS, Wood DE, Aisner DL, Akerley W. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 5.2021. Published June 15, 2021. Accessed March 25, 2021. doi:10.6004/jnccn.2021.001
2. Karlsen EA, Kahler S, Tefay J, Joseph SR, Simpson F. Epidermal growth factor receptor expression and resistance patterns to targeted therapy in non-small cell lung cancer: A review. Cells. 2021;10(5):1206. Published 2021 May 14. doi:10.3390/cells10051206
3. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med*. 2018;378(2):113-125. doi:10.1056/NEJMoa1713137
4. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. *N Engl J Med*. 2020;382(1):41-50. doi:10.1056/NEJMoa1913662
5. Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*. 2016;17(12):1643-1652. doi:10.1016/S1470-2045(16)30508-3
6. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med*. 2015;372(18):1689-1699. doi:10.1056/NEJMoa1411817

Question 13:

1. Peters S, Reck M, Smit EF, Mok T, Hellmann MD. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. *Ann Oncol*. 2019;30(6):884-896. doi:10.1093/annonc/mdz109
2. Leonardi GC, Gainor JF, Altan M, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. *J Clin Oncol*. 2018;36(19):1905-1912. doi:10.1200/JCO.2017.77.0305
3. Khan SA, Pruitt SL, Xuan L, Gerber DE. Prevalence of autoimmune disease among patients with lung cancer: Implications for immunotherapy treatment options. *JAMA Oncol*. 2016;2(11):1507-1508. doi:10.1001/jamaoncol.2016.2238

Question 14:

1. FDA Press Release. FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer. Published May 21, 2021. Accessed August 11, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-subset-non-small-cell-lung-cancer
2. Sabari JK. Amivantamab in post-platinum EGFR Exon 20 insertion mutant non-small cell lung cancer. Presented at: 2020 World Conference on Lung Cancer; January 28 - 31, 2021; Singapore. https://library.iaslc.org/conference-program?product_id=20&author=&category=&date=&session_type=&session=&presentation=&keyword=sabari&cme=undefined&
3. Remon J, Hendriks LEL, Cardona AF, Besse B. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. *Cancer Treat Rev*. 2020;90:102105. doi:10.1016/j.ctrv.2020.102105
4. Lam V et al. P2.03b-023 Circulating tumor DNA (ctDNA)-based genomic profiling of known cancer genes in lung squamous cell carcinoma (LUSC). Presented at: 2017 World Conference on Lung Cancer; October 15-18, 2017; Yokohoma, Japan. doi:https://doi.org/10.1016/j.jtho.2016.11.1304

Question 15:

1. Gadgeel SM. FDA Approves Afatinib for squamous cell lung cancer. Published April 15, 2016. Accessed August 11, 2021. https://www.onclive.com/view/fda-approves-afatinib-for-squamous-cell-lung-cancer
2. Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol*. 2015;16(8):897-907. doi:10.1016/S1470-2045(15)00006-6
3. Felip E, Hirsh V, Popat S, et al. Symptom and quality of life improvement in LUX-Lung 8, an open-label phase III study of second-line afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung after first-line platinum-based chemotherapy. *Clin Lung Cancer*. 2018;19(1):74-83.e11. doi:10.1016/j.cllc.2017.06.002

Question 16:

1. Santos ES, Hart L. Advanced squamous cell carcinoma of the lung: Current treatment approaches and the role of afatinib. *Onco Targets Ther.* 2020;13:9305-9321. Published 2020 Sep 22. doi:10.2147/OTT.S250446
2. Gadgeel SM. FDA Approves Afatinib for squamous cell lung cancer. Published April 15, 2016. Accessed August 11, 2021. https://www.onclive.com/view/fda-approves-afatinib-for-squamous-cell-lung-cancer
3. Bonomi PD, Gandara D, Hirsch FR, et al. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. *Ann Oncol.* 2018;29(8):1701-1709. doi:10.1093/annonc/mdy196

Question 17:

1. Karachaliou N, Fernandez-Bruno M, Bracht JWP, et al. EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients. *Transl Cancer Res* 2019;8(Suppl 1):S23-S47. doi:10.21037/tcr.2018.10.06
2. Boehringer Ingelheim Pharmaceuticals, Inc. GILOTRIF® (afatinib) tablets, for oral use [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised 10/2019. Accessed August 11, 2021.

Question 18:

1. Maione P, Sgambato A, Casaluce F, et al. The role of the antiangiogenetic ramucirumab in the treatment of advanced non-small cell lung cancer. *Curr Med Chem.* 2017;24(1):3-13. doi:10.2174/0929867324666161118125103
2. Tsironis G, Ziogas DC, Kyriazoglou A, et al. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. *Ann Transl Med.* 2018;6(8):143. doi:10.21037/atm.2018.02.18
3. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet.* 2014;384(9944):665-673. doi:10.1016/S0140-6736(14)60845-X

Question 19:

1. Davies MJ. PD-1/PD-L1 inhibitors for non-small cell lung cancer: Incorporating care step pathways for effective side-effect management. *J Adv Pract Oncol.* 2019;10(Suppl 1):21-35. doi:10.6004/jadpro.2019.10.2.11

Question 20:

1. Davies MJ. PD-1/PD-L1 inhibitors for non-small cell lung cancer: Incorporating care step pathways for effective side-effect management. *J Adv Pract Oncol.* 2019;10(Suppl 1):21-35. doi:10.6004/jadpro.2019.10.2.11
2. Thompson JA, Schneider JA, Brahmer J, et al. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Management of Immune Checkpoint Inhibitor-Related Toxicities V3.2021. Published May 14, 2021. Accessed August 11, 2021. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

Question 21:

2. Boehringer Ingelheim Pharmaceuticals, Inc. GILOTRIF® (afatinib) tablets, for oral use [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised 10/2019. Accessed August 11, 2021.

Question 22:

1. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet.* 2014;384(9944):665-673. doi:10.1016/S0140-6736(14)60845-X
2. Kurzrock R, Stewart DJ. Exploring the benefit/risk associated with antiangiogenic agents for the treatment of non-small cell lung cancer patients. *Clin Cancer Res.* 2017;23(5):1137-1148. doi:10.1158/1078-0432.CCR-16-1968

Question 23:

1. Tattersall IW, Leventhal JS. Cutaneous toxicities of immune checkpoint inhibitors: The role of the dermatologist. *Yale J Biol Med.* 2020;93(1):123-132. Published 2020 Mar 27.
2. AIM with Immunotherapy Foundation. Care Step Pathway - Skin Toxicities. Immuno-oncology Essentials. Published 2018. Accessed August 11, 2021. http://aimwithimmunotherapy.org/wp-content/uploads/2019/05/IOE-CSP1-skintoxicity_final.pdf
3. Thompson JA, Schneider JA, Brahmer J, et al. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Management of Immune Checkpoint Inhibitor-Related Toxicities V3.2021. Published May 14, 2021. Accessed August 11, 2021. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf
4. Merck. KEYTRUDA® (pembrolizumab) injection, for intravenous use [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s102lbl.pdf. Revised 08/2021. Accessed August 11, 2021.